Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
120.46
+0.19 (0.16%)
Feb 23, 2026, 3:43 PM EST - Market open
Glaukos Revenue
In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth. Glaukos had revenue of $143.12M in the quarter ending December 31, 2025, with 35.66% growth.
Revenue (ttm)
$507.44M
Revenue Growth
+32.33%
P/S Ratio
13.46
Revenue / Employee
$509,992
Employees
995
Market Cap
6.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
| Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
| Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
| Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
| Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
| Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
| Dec 31, 2013 | 20.95M | 18.52M | 762.33% |
| Dec 31, 2012 | 2.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Smith & Nephew | 5.94B |
| Bruker | 3.44B |
| Globus Medical | 2.77B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Masimo | 2.18B |
| Integer Holdings | 1.85B |
| LivaNova | 1.35B |
GKOS News
- 5 days ago - These Analysts Boost Their Forecasts On Glaukos Following Q4 Results - Benzinga
- 5 days ago - Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 20 days ago - Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards - Seeking Alpha
- 24 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 26 days ago - Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR - Business Wire
- 4 weeks ago - Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 - Business Wire
- 5 weeks ago - Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha